310 related articles for article (PubMed ID: 26189041)
1. Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma.
Gu L; Xie L; Zuo C; Ma Z; Zhang Y; Zhu Y; Gao J
BMC Cancer; 2015 Jul; 15():529. PubMed ID: 26189041
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.
Gu L; Gao J; Li Q; Zhu YP; Jia CS; Fu RY; Chen Y; Liao QK; Ma Z
Leukemia; 2008 Nov; 22(11):2091-6. PubMed ID: 18685609
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis.
Gu L; Zhou C; Liu H; Gao J; Li Q; Mu D; Ma Z
J Exp Clin Cancer Res; 2010 Nov; 29(1):150. PubMed ID: 21083937
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and up-regulation and activation of glucocorticoid receptor.
Guo X; Zhou CY; Li Q; Gao J; Zhu YP; Gu L; Ma ZG
Biomed Environ Sci; 2013 May; 26(5):371-81. PubMed ID: 23611130
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of autophagy overcomes glucocorticoid resistance in lymphoid malignant cells.
Jiang L; Xu L; Xie J; Li S; Guan Y; Zhang Y; Hou Z; Guo T; Shu X; Wang C; Fan W; Si Y; Yang Y; Kang Z; Fang M; Liu Q
Cancer Biol Ther; 2015; 16(3):466-76. PubMed ID: 25778879
[TBL] [Abstract][Full Text] [Related]
7. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells.
Bishop JD; Nien WL; Dauphinee SM; Too CK
J Endocrinol; 2006 Aug; 190(2):307-12. PubMed ID: 16899564
[TBL] [Abstract][Full Text] [Related]
8. [Synergistic effect of rapamycin (RPM) and PD98059 on cell cycle and mTOR signal transduction in human colorectal cancer cells].
Zhang YJ; Fang JY; Sun DF; Zhao SL; Shen GF; Zheng Q; Zhu HY
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):889-93. PubMed ID: 18478925
[TBL] [Abstract][Full Text] [Related]
9. [Effects of mTOR Inhibitor Rapamycin on Burkitt's Lymphoma Cells].
Zhou LH; Zhu XP; Xiao HF; Xin PL; Li CT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1397-1405. PubMed ID: 29070114
[TBL] [Abstract][Full Text] [Related]
10. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
Yan H; Frost P; Shi Y; Hoang B; Sharma S; Fisher M; Gera J; Lichtenstein A
Cancer Res; 2006 Feb; 66(4):2305-13. PubMed ID: 16489035
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone.
Strömberg T; Dimberg A; Hammarberg A; Carlson K; Osterborg A; Nilsson K; Jernberg-Wiklund H
Blood; 2004 Apr; 103(8):3138-47. PubMed ID: 15070696
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
[TBL] [Abstract][Full Text] [Related]
13. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma.
Li SH; Chen CH; Lu HI; Huang WT; Tien WY; Lan YC; Lee CC; Chen YH; Huang HY; Chang AY; Lin WC
Surgery; 2015 Mar; 157(3):570-80. PubMed ID: 25726316
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.
Li H; Kong X; Cui G; Ren C; Fan S; Sun L; Zhang Y; Cao R; Li Y; Zhou J
Int J Hematol; 2015 Nov; 102(5):558-68. PubMed ID: 26362858
[TBL] [Abstract][Full Text] [Related]
16. [Blockage of mTOR signaling pathway by rapamycin contributes to inhibition of tumor cell proliferation in ALK-positive lymphoid cell strains].
Gu L; Li JF; Gao J; Zhu YP; Li Q; Jia CS; Zhou CY; Ma ZG
Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):662-6. PubMed ID: 19176057
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
[TBL] [Abstract][Full Text] [Related]
18. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models.
Chang Q; Chen E; Hedley DW
Cancer Biol Ther; 2009 Oct; 8(20):1893-901. PubMed ID: 20009539
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells.
Xu RH; Pelicano H; Zhang H; Giles FJ; Keating MJ; Huang P
Leukemia; 2005 Dec; 19(12):2153-8. PubMed ID: 16193082
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
Li J; Xue L; Hao H; Han Y; Yang J; Luo J
Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
